Sept. 21st Webinar: Hepatocellular Drug Disposition Profiling Using Sandwich-Cultured Hepatocytes by D-PREX Assay
Presenter: Dr. Katsuhiro Kanda, Senior Engineer in Bio Systems Design at Hitachi High-Tech Corporation
D-PREXⓇ is an assay methodology to evaluate total hepatocellular drug dispositions from drug uptake to both biliary and basolateral efflux simultaneously. D-PREXⓇ is predominantly utilized to assess supernatant fractions collected by a systematic assay procedure following consistent analysis and time-course sampling. In addition, D-PREXⓇ only exposes drugs to intact cell cultures, which leads to intracellular metabolism, resulting in simultaneous assessment of not only parent compounds but also their metabolite distributions. In this webinar, a technological overview will be presented along with assay examples of D-PREXⓇ, which is currently available as a contract research service by SEKISUI Medical supported by SEKISUI XenoTech. “D-PREX” is a registered trademark of Hitachi High-Tech Corporation in the US and Japan.
Key concepts discussed in this webinar will include:
- Technological overview and principle of D-PREXⓇ assay
- Sequential sampling of supernatants prior to final cell lysate sampling for reproducible, high-throughput analyses
- Simultaneous evaluation of biliary and basolateral efflux from identical cell culture samples
- Simultaneous profiling of parent compounds and metabolite distributions
- Understanding the overall picture of drug and metabolite hepatocellular disposition profiles from the complex interplay of hepatic transport and metabolism
(registrants will receive a copy of the slides and a link to the recording on Sept. 21, 2021)
About the Presenter:
Dr. Katsuhiro Kanda is currently a Senior Engineer in the Bio Systems Design Department of Hitachi High-Tech Corporation. He received his B.Agr. and M.A. degree from the University of Tsukuba, and engaged as a research scientist in several biotech institutes. He received his Ph.D. from Iwate University and conducted research as a lecturer until joining the Life Science Group of Hitachi Ltd. in 2000. Since then, he has been challenged with the task of creating innovative technology and products primarily based on biochemical insights.